IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient

The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133(+)-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Forcillo, Jessica, Stevens, Louis-Mathieu, Mansour, Samer, Prieto, Ignacio, Roy, Denis-Claude, Noiseux, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505958/
https://www.ncbi.nlm.nih.gov/pubmed/23213603
http://dx.doi.org/10.1155/2011/685394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505958/
https://www.ncbi.nlm.nih.gov/pubmed/23213603
http://dx.doi.org/10.1155/2011/685394

Ejemplares similares